These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 2557776

  • 1. Effects of ethanol on human platelets stimulated with platelet-activating factor, a biologically active ether phospholipid.
    Baker RC, Fish HT, Fitzpatrick FA.
    Alcohol Clin Exp Res; 1989 Dec; 13(6):824-8. PubMed ID: 2557776
    [Abstract] [Full Text] [Related]

  • 2. Effects of ethanol on pathways of platelet aggregation in vitro.
    Rand ML, Packham MA, Kinlough-Rathbone RL, Fraser Mustard J.
    Thromb Haemost; 1988 Jun 16; 59(3):383-7. PubMed ID: 3142075
    [Abstract] [Full Text] [Related]

  • 3. Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation.
    Nunn B.
    Thromb Res; 1983 Sep 01; 31(5):657-63. PubMed ID: 6648898
    [Abstract] [Full Text] [Related]

  • 4. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
    Patscheke H, Stegmeier K.
    Thromb Res; 1984 Feb 01; 33(3):277-88. PubMed ID: 6424261
    [Abstract] [Full Text] [Related]

  • 5. Bakkenolide G, a natural PAF-receptor antagonist.
    Liao CH, Ko FN, Wu TS, Teng CM.
    J Pharm Pharmacol; 1997 Dec 01; 49(12):1248-53. PubMed ID: 9466352
    [Abstract] [Full Text] [Related]

  • 6. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
    Sanderson HM, Heptinstall S, Vickers J, Lösche W.
    Blood Coagul Fibrinolysis; 1996 Mar 01; 7(2):245-8. PubMed ID: 8735830
    [Abstract] [Full Text] [Related]

  • 7. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S, Westwick J, Kakkar VV.
    Biochem Pharmacol; 1984 Oct 01; 33(19):3025-35. PubMed ID: 6091666
    [Abstract] [Full Text] [Related]

  • 8. Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation.
    Fouque F, Vargaftig BB.
    Br J Pharmacol; 1984 Nov 01; 83(3):625-33. PubMed ID: 6439269
    [Abstract] [Full Text] [Related]

  • 9. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS, Johns A, Kleha J, Xie J, Wang Y, Bianchi J, Conley K.
    J Pharmacol Exp Ther; 1994 Mar 01; 268(3):1352-61. PubMed ID: 8138950
    [Abstract] [Full Text] [Related]

  • 10. Thromboxane receptor activation during bronchospasm induced by platelet-activating factor.
    Schumacher WA, Steinbacher TE.
    J Lipid Mediat; 1991 Mar 01; 4(1):97-110. PubMed ID: 1832573
    [Abstract] [Full Text] [Related]

  • 11. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P, White BP, Humphrey PP.
    Br J Pharmacol; 1989 Jul 01; 97(3):783-94. PubMed ID: 2527074
    [Abstract] [Full Text] [Related]

  • 12. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound.
    Ding YA, Chou TC, Chern JW, Yen MH.
    Thromb Res; 1995 Feb 01; 77(3):291-303. PubMed ID: 7740521
    [Abstract] [Full Text] [Related]

  • 13. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA, Jones RL, Peesapati V, Will SG, Wilson NH.
    Br J Pharmacol; 1985 Mar 01; 84(3):595-607. PubMed ID: 2580580
    [Abstract] [Full Text] [Related]

  • 14. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R, Mezzasoma AM, Venditti G, Gresele P.
    Thromb Haemost; 2002 Jan 01; 87(1):114-21. PubMed ID: 11848439
    [Abstract] [Full Text] [Related]

  • 15. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
    Suzuki M, Sugatani J, Ino M, Shimura M, Akiyama M, Yamazaki R, Suzuki Y, Miwa M.
    Am J Physiol; 1998 Jan 01; 274(1):C47-57. PubMed ID: 9458712
    [Abstract] [Full Text] [Related]

  • 16. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K, Halushka PV, Yan YT, Wong PY.
    J Pharmacol Exp Ther; 1994 Sep 01; 270(3):1192-6. PubMed ID: 7932171
    [Abstract] [Full Text] [Related]

  • 17. Platelet desensitization by arachidonic acid is associated with the suppression of endoperoxide/thromboxane A2 binding to the membrane receptor.
    Sato T, Hashizume T, Nakao K, Akiba S, Fujii T.
    Biochim Biophys Acta; 1989 Aug 18; 992(2):168-73. PubMed ID: 2503041
    [Abstract] [Full Text] [Related]

  • 18. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
    Furci L, Fitzgerald DJ, Fitzgerald GA.
    J Pharmacol Exp Ther; 1991 Jul 01; 258(1):74-81. PubMed ID: 1830100
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
    Patscheke H, Stegmeier K, Müller-Beckmann B, Sponer G, Staiger C, Neugebauer G.
    Biomed Biochim Acta; 1984 Jul 01; 43(8-9):S312-8. PubMed ID: 6097235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.